

Exhibit 1007

DECLARATION OF MATTHEW W. DAVIS M.D. RPH.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re *Inter Partes Review* : PETITION FOR *INTER PARTES* REVIEW OF
U.S. PATENT NO. 6,045,501 UNDER 35 USC §§
311-319 AND 37 CFR §42.100 ET SEQ.

Case No. : To be Assigned

Petitioner : To be Named

Filed :

Attorney Docket No. :

Customer No. : 27571

Appeal Related Matters

Patent Trial and Appeal Board

US Patent and Trademark Office

PO Box 1450

Alexandria, Virginia 22313-1450

DECLARATION OF MATTHEW W. DAVIS M.D. R.Ph.

Sir:

I, the undersigned, hereby declare the following, based on my own
knowledge, information, and belief:

1. I am presently Senior Vice President of Clinical Operations and Development at Sun Pharmaceuticals.

2. I received an M.D. degree from the Medical College of Pennsylvania in 1994, a B.S. in Pharmacy from Temple University School of Pharmacy. I did an internship in surgery, followed by a residency in urology. I am a pharmacist, R.Ph, as well as a licensed physician.

3. Since 1998, I have directed clinical development, medical affairs and pharmacovigilance at a number of different companies. These companies include, Endo Pharmaceuticals, Dermik Laboratories, Dr. Reddy's Laboratories, Eisai Global Research and most recently, URL Pharma, now Sun Pharmaceuticals.

4. I have co-authored 20 articles in peer reviewed scientific and medical journals. I am the sole inventor of 17 U.S. patents, named inventor on numerous other patents and patent applications. A copy of my resume is attached.

5. I have reviewed U.S. Patent No. 6,045,501, its file history as well as the prior art cited in the Petition: (i) Dishman et al. (Am. J. Hosp. Pharm 51: 899

(1994), (“Dishman”), *Exhibit 1004*); (ii) Bastani et al. (Psychopharmacology 99:S122 (1989), (“Bastani”), *Exhibit 1005*); (iii) Powell et al. (Postgrad. Med. J. 70:901 (1994), (“Powell”), *Exhibit 1006*); (iv) Mitchell et al. (New England J. Med. 333(2):101 (1995), (“Mitchell”), *Exhibit 1008*); (v) Honigfeld (Psychiatric Services 47:52 (1996), (“Honigfeld”) (*Exhibit 1009*); (vi) the 47th Meeting of the Dermatologic and Ophthalmic Advisory Board (September 4-5, 1997, (the “FDA Meeting”), *Exhibit 1010 (a) and (b)*); and (vii) CDC Meeting (Centers for Disease Control, Preventing Birth Defects, March 26, 1997, (*Exhibit 1011*) (the “CDC Meeting”)).

6. Dishman discloses a program instituted by the Department of Veterans Affairs (VA) for controlling the dispensing of an antipsychotic drug, clozapine. *Exhibit 1004*, Abstract. Because clozapine treatment is associated with a number of serious and potentially fatal serious side effects, its use needs to be tightly controlled. *Exhibit 1005 at S122*. In 1994, the VA developed a clozapine monitoring program. *Exhibit 1004 at 900*. A National Clozapine Coordinating Center (NCCC) was established. *Id.* The NCCC required that each hospital have a computerized clozapine prescription lockout system, which ties the hospital’s laboratory database to the outpatient pharmacy dispensing software. *Id.* The program only allows clozapine prescriptions to be processed when the white blood

cell counts are within defined limits, i.e., when certain pre-defined clinical criteria are met. *Id.* The NCCC guidelines require extensive patient evaluation and documentation. In order to receive clozapine, the patients have to undergo a complete physical examination, including laboratory tests. *Id.* Patients are screened by the pharmacist to determine eligibility for treatment with clozapine. *Id.* The pharmacist then sends the information to the NCCC and after approval, the patient is then enrolled in the hospital's clozapine tracking system and therapy is begun. *Id.* In other words, the clozapine monitoring system in the VA, provides for (i) "registration into one or more computer readable storage media of the prescriber, pharmacy and patient"; (ii) "a means to monitor and authorize distribution of contraindicated drugs, including teratogenic drugs"; and (iii) denial of "dispensation or prescriptions of contraindicated drugs, including teratogenic drugs, to patients, pharmacies or prescribers who fail to abide by the methods of the present invention". *Exhibit 1001 at 10:13-20.* A similar clozapine monitoring system has been instituted at numerous other hospitals throughout the U.S., for example, see the Clozaril Patient Management System (CPMS), *Exhibit 1005.* The CPMS program provides for extensive counseling of patients, including meetings with physicians, psychiatric research technicians and supportive group therapy. *Id. at S123.*

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.